Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs
暂无分享,去创建一个
Christopher J. H. Porter | David M. Shackleford | G. Edwards | C. Porter | W. Charman | S. Khoo | William N. Charman | Glenn A. Edwards | Shui-Mei Khoo
[1] C. Porter,et al. Uptake of drugs into the intestinal lymphatics after oral administration , 1997 .
[2] G. Edwards,et al. Animal models for the study of intestinal lymphatic drug transport. , 2001, Advanced drug delivery reviews.
[3] C. Porter,et al. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. , 2000, Journal of pharmaceutical sciences.
[4] G. Edwards,et al. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. , 2002, Journal of pharmaceutical sciences.
[5] C. Porter,et al. Desbutylhalofantrine: Evaluation of QT Prolongation and Other Cardiovascular Effects after Intravenous Administration In Vivo , 2003, Journal of cardiovascular pharmacology.
[6] G. Edwards,et al. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine , 1998 .
[7] C. Porter,et al. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. , 1995, Journal of pharmaceutical and biomedical analysis.
[8] C. Porter. Drug delivery to the lymphatic system. , 1997, Critical reviews in therapeutic drug carrier systems.
[9] K. Isselbacher,et al. Very low density lipoproteins in intestinal lymph: origin, composition, and role in lipid transport in the fasting state. , 1969, The Journal of clinical investigation.
[10] D. Capuzzi,et al. Intestinal triglycerides are derived from both endogenous and exogenous sources. , 1985, The American journal of physiology.
[11] D. Hauss,et al. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach , 1994 .
[12] J. Dressman,et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.
[13] C. Porter,et al. Model systems for intestinal lymphatic transport studies. , 1996, Pharmaceutical biotechnology.
[14] C. Porter,et al. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. , 1996, Journal of pharmaceutical sciences.
[15] K. Isselbacher,et al. Very low density lipoproteins in intestinal lymph: role in triglyceride and cholesterol transport during fat absorption. , 1969, The Journal of clinical investigation.
[16] C. Mansbach,et al. Factors influencing triacylglycerol delivery into mesenteric lymph. , 1985, The American journal of physiology.
[17] C. Porter,et al. The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. , 2000, International journal of pharmaceutics.
[18] V. Stella,et al. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules , 1986 .
[19] G. Edwards,et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. , 2001, Journal of pharmaceutical sciences.